Top

Published in:

Open Access 01-12-2004 | Review

Using animal models to determine the significance of complement activation in Alzheimer's disease

Author: David A Loeffler

Published in: Journal of Neuroinflammation | Issue 1/2004

Abstract

Complement inflammation is a major inflammatory mechanism whose function is to promote the removal of microorganisms and the processing of immune complexes. Numerous studies have provided evidence for an increase in this process in areas of pathology in the Alzheimer's disease (AD) brain. Because complement activation proteins have been demonstrated in vitro to exert both neuroprotective and neurotoxic effects, the significance of this process in the development and progression of AD is unclear. Studies in animal models of AD, in which brain complement activation can be experimentally altered, should be of value for clarifying this issue. However, surprisingly little is known about complement activation in the transgenic animal models that are popular for studying this disorder. An optimal animal model for studying the significance of complement activation on Alzheimer's – related neuropathology should have complete complement activation associated with senile plaques, neurofibrillary tangles (if present), and dystrophic neurites. Other desirable features include both classical and alternative pathway activation, increased neuronal synthesis of native complement proteins, and evidence for an increase in complement activation prior to the development of extensive pathology. In order to determine the suitability of different animal models for studying the role of complement activation in AD, the extent of complement activation and its association with neuropathology in these models must be understood.

Available only for authorised users

Bamberger ME, Landreth GE: Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist. 2002, 8: 276-283.PubMed

Gupta A, Pansari K: Inflammation and Alzheimer's disease. Int J Clin Pract. 2003, 57: 36-39.PubMed

Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P: The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications. Drugs Today (Barc). 2002, 38: 429-443.

McGeer EG, McGeer PL: Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27: 741-749. 10.1016/S0278-5846(03)00124-6.PubMed

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging. 2000, 21: 383-421. 10.1016/S0197-4580(00)00124-X.PubMedCentralPubMed

Combs CK, Karlo JC, Kao SC, Landreth GE: beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001, 21: 1179-1188.PubMed

Griffin WS, Mrak RE: Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol. 2002, 72: 233-238.PubMedCentralPubMed

Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE: Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998, 8: 65-72.PubMed

McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996, 47: 425-432.PubMed

10.

Benveniste EN, Nguyen VT, O'Keefe GM: Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int. 2001, 39: 381-391. 10.1016/S0197-0186(01)00045-6.PubMed

11.

Meda L, Baron P, Scarlato G: Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol Aging. 2001, 22: 885-893. 10.1016/S0197-4580(01)00307-4.PubMed

12.

Mrak RE, Griffin WS: The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 2001, 22: 915-922. 10.1016/S0197-4580(01)00293-7.PubMed

13.

Emmerling MR, Watson MD, Raby CA, Spiegel K: The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta. 2000, 1502: 158-171.PubMed

14.

McGeer PL, McGeer EG: The possible role of complement activation in Alzheimer disease. Trends Mol Med. 2002, 8: 519-523. 10.1016/S1471-4914(02)02422-X.PubMed

15.

Tenner AJ: Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 2001, 22: 849-861. 10.1016/S0197-4580(01)00301-3.PubMed

16.

Abraham CR: Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging. 2001, 22: 931-936. 10.1016/S0197-4580(01)00302-5.PubMed

17.

Kovacs DM: alpha2-macroglobulin in late-onset Alzheimer's disease. Exp Gerontol. 2000, 35: 473-479. 10.1016/S0531-5565(00)00113-3.PubMed

18.

Loeffler DA, Sima AA, LeWitt PA: Ceruloplasmin immunoreactivity in neurodegenerative disorders. Free Radic Res. 2001, 35: 111-118.PubMed

19.

Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R: Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993, 629: 245-252. 10.1016/0006-8993(93)91327-O.PubMed

20.

McGeer PL, Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 1992, 42: 447-449.PubMed

21.

Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F: Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993, 43: 1609-1611.PubMed

22.

Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000, 54: 588-593.PubMed

23.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003, 289: 2819-2826. 10.1001/jama.289.21.2819.PubMed

24.

Sainetti SM, Ingram DM, Talwalker S, Geis GS: Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease [abstract]. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. 2000, 180-

25.

Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ, Scheltens PK: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001, 358: 455-460. 10.1016/S0140-6736(01)05623-9.PubMed

26.

Shen Y, Meri S: Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol. 2003, 70: 463-472.PubMed

27.

Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease–a double-edged sword. Neuron. 2002, 35: 419-432. 10.1016/S0896-6273(02)00794-8.PubMed

28.

Neumann H: The immunological microenvironment in the CNS: implications on neuronal cell death and survival. J Neural Transm Suppl. 2000, 59: 59-68.PubMed

29.

Polazzi E, Contestabile A: Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev Neurosci. 2002, 13: 221-242.PubMed

30.

van Beek J, Elward K, Gasque P: Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci. 2003, 992: 56-71.PubMed

31.

Barnum SR: Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med. 1995, 6: 132-146.PubMed

32.

Eikelenboom P, Hack CE, Rozemuller JM, Stam FC: Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989, 56: 259-262.PubMed

33.

Eikelenboom P, Stam FC: Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (Berl). 1982, 57: 239-42.

34.

Eikelenboom P, Stam FC: An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1984, 47: 17-25.PubMed

35.

Ishii T, Haga S: Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol (Berl). 1984, 63: 296-300.

36.

Veerhuis R, Janssen I, Hack CE, Eikelenboom P: Early complement components in Alzheimer's disease brains. Acta Neuropathol (Berl). 1996, 91: 53-60. 10.1007/s004019570001.

37.

Veerhuis R, van der Valk P, Janssen I, Zhan SS, Van Nostrand WE, Eikelenboom P: Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch. 1995, 426: 603-610. 10.1007/BF00192116.PubMed

38.

Itagaki S, Akiyama H, Saito H, McGeer PL: Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 1994, 645: 78-84. 10.1016/0006-8993(94)91640-3.PubMed

39.

Lue LF, Brachova L, Civin WH, Rogers J: Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996, 55: 1083-1088.PubMed

40.

McGeer PL, Akiyama H, Itagaki S, McGeer EG: Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989, 107: 341-346. 10.1016/0304-3940(89)90843-4.PubMed

41.

McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG: Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 1991, 544: 315-319. 10.1016/0006-8993(91)90071-3.PubMed

42.

Webster S, Lue L-F, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging. 1997, 18: 415-421. 10.1016/S0197-4580(97)00042-0.PubMed

43.

Webster S, Glabe C, Rogers J: Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995, 217: 869-875. 10.1006/bbrc.1995.2852.PubMed

44.

Webster S, O'Barr S, Rogers J: Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994, 39: 448-456.PubMed

45.

Schultz J, Schaller J, McKinley M, Bradt B, Cooper N, May P, Rogers J: Enhanced cytotoxicity of amyloid beta-peptide by a complement dependent mechanism. Neurosci Lett. 1994, 175: 99-102. 10.1016/0304-3940(94)91088-X.PubMed

46.

Nolte C, Moller T, Walter T, Kettenmann H: Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience. 1996, 73: 1091-1107. 10.1016/0306-4522(96)00106-6.PubMed

47.

Yao J, Harvath L, Gilert DL, Colton CA: Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res. 1990, 27: 36-42.PubMed

48.

O'Barr S, Cooper NR: The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol. 2000, 109: 87-94. 10.1016/S0165-5728(00)00291-5.PubMed

49.

Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P: Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1–42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol (Berl). 2003, 105: 135-144.

50.

Shen Y, Halperin JA, Lee CM: Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 1995, 671: 282-292. 10.1016/0006-8993(94)01264-I.PubMed

51.

Osaka H, Mukherjee P, Aisen PS, Pasinetti GM: Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999, 73: 303-311. 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.3.CO;2-U.PubMed

52.

van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, Fontaine M: Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport. 2001, 12: 289-293. 10.1097/00001756-200102120-00022.PubMed

53.

O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol. 2001, 166: 4154-4162.PubMed

54.

Mukherjee P, Pasinetti GM: Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem. 2001, 77: 43-49. 10.1046/j.1471-4159.2001.00167.x.PubMed

55.

Soane L, Cho HJ, Niculescu F, Rus H, Shin ML: C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. 2001, 167: 2305-2311.PubMed

56.

Frautschy SA, Hammer H, Hu S, Hu W, Oh M, Miller SA, Lim GP, Harris-White ME, Tenner AJ: C1q stimulates Abeta clearance but worsens memory in Alzheimer model: too much C1q may be worse than too little. Program No. 667.12. Abstract Viewer/Itinerary Planner. 2003, Washington, DC: Society for Neuroscience

57.

Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ: Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol. 2000, 161: 127-138. 10.1006/exnr.1999.7260.PubMed

58.

Sahu A, Lambris JD: Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacol. 2000, 49: 133-148. 10.1016/S0162-3109(00)80299-4.

59.

Morgan BP, Harris CL: Complement therapeutics; history and current progress. Mol Immunol. 2003, 40: 159-170. 10.1016/S0161-5890(03)00111-1.PubMed

60.

De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, Rossi E, Bergamaschini L: Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab. 2003, 23: 232-239. 10.1097/00004647-200302000-00010.PubMed

61.

Kirschfink M: C1-inhibitor and transplantation. Immunobiology. 2002, 205: 534-541.PubMed

62.

Quigg RJ: Role of complement and complement regulatory proteins in glomerulonephritis. Springer Semin Immunopathol. 2003, 24: 395-410. 10.1007/s00281-002-0116-9.PubMed

63.

de Zwaan C, van Dieijen-Visser MP, Hermens WT: Prevention of cardiac cell injury during acute myocardial infarction: possible role for complement inhibition. Am J Cardiovasc Drugs. 2003, 3: 245-251.PubMed

64.

Farkas H, Harmat G, Fust G, Varga L, Visy B: Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002, 13: 153-161. 10.1034/j.1399-3038.2002.01014.x.PubMed

65.

Rozemuller AJ, Eikelenboom P, Theeuwes JW, Jansen Steur EN, de Vos RA: Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol (Berl). 2000, 100: 701-708. 10.1007/s004010000225.

66.

Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA: Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol. 2000, 156: 489-499.PubMedCentralPubMed

67.

Rostagno A, Revesz T, Lashley T, Tomidokoro Y, Magnotti L, Braendgaard H, Plant G, Bojsen-Moller M, Holton J, Frangione B, Ghiso J: Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem. 2002, 277: 49782-49790. 10.1074/jbc.M206448200.PubMed

68.

Bradt BM, Kolb WP, Cooper NR: Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med. 1998, 188: 431-438. 10.1084/jem.188.3.431.PubMedCentralPubMed

69.

Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I: Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992, 89: 10016-10020.PubMedCentralPubMed

70.

Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, Goux WJ, Lee V, Johnson GV, Webster SD, Cooper NR, Bradt B, Rogers J: Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett. 2001, 305: 165-168. 10.1016/S0304-3940(01)01842-0.PubMed

71.

Webster S, Bradt B, Rogers J, Cooper N: Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem. 1997, 69: 388-398.PubMed

72.

Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, Agostoni A: Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Clin Exp Immunol. 1999, 115: 526-533. 10.1046/j.1365-2249.1999.00835.x.PubMedCentralPubMed

73.

Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, McGeer PL: Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia. 1999, 25: 324-331. 10.1002/(SICI)1098-1136(19990215)25:4<324::AID-GLIA2>3.0.CO;2-5.PubMed

74.

Rozemuller JM, van der Valk P, Eikelenboom P: Activated microglia and cerebral amyloid deposits in Alzheimer's disease. Res Immunol. 1992, 143: 646-649.PubMed

75.

Lue LH, Rogers J: Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia. 1992, 3: 308-313.

76.

Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ: Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis. 2004, 15: 40-46. 10.1016/j.nbd.2003.09.004.PubMed

77.

Loeffler DA, Camp DM, Schonberger M, Singer DJ, LeWitt PA: ELISA measurement of C4d and iC3b in Alzheimer's disease and normal brain specimens. Neurobiol Aging. 2004, 25: 1001-1007. 10.1016/j.neurobiolaging.2003.11.003.PubMed

78.

Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997, 769: 391-395. 10.1016/S0006-8993(97)00850-0.PubMed

79.

Walker DG, McGeer PL: Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res. 1992, 14: 109-116. 10.1016/0169-328X(92)90017-6.PubMed

80.

Yasojima K, Schwab C, McGeer EG, McGeer PL: Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol. 1999, 154: 927-936.PubMedCentralPubMed

81.

Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL: Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 1995, 675: 75-82. 10.1016/0006-8993(95)00041-N.PubMed

82.

Yasojima K, McGeer EG, McGeer PL: Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res. 1999, 833: 297-301. 10.1016/S0006-8993(99)01514-0.PubMed

83.

Yang L-B, Li R, Meri S, Rogers J, Shen Y: Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci. 2000, 20: 7505-7509.PubMed

84.

Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J: Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol. 2002, 131: 135-146. 10.1016/S0165-5728(02)00272-2.PubMed

85.

Strohmeyer R, Shen Y, Rogers J: Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res. 2000, 81: 7-18. 10.1016/S0169-328X(00)00149-2.PubMed

86.

Janus C, Phinney AL, Chishti MA, Westaway D: New developments in animal models of Alzheimer's disease. Curr Neurol Neurosci Rep. 2001, 1: 451-457.PubMed

87.

Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L: TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001, 7: 612-618. 10.1038/87945.PubMed

88.

Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E: Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 2002, 99: 10837-10842. 10.1073/pnas.162350199.PubMedCentralPubMed

89.

Lindorfer MA, Hahn CS, Foley PL, Taylor RP: Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev. 2001, 183: 10-24. 10.1034/j.1600-065x.2001.1830102.x.PubMed

90.

Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM: Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med. 1992, 175: 121-129. 10.1084/jem.175.1.121.PubMed

91.

Yu JX, Bradt BM, Hsiao K, Carrol MC, Cooper NR: Amyloid plaques in a transgenic mouse model of Alzheimer's disease contain complement components and pro-inflammatory cytokines. Program No. 491.1. 2000 Abstract Viewer/Itinerary Planner. 2000, Washington, DC: Society for Neuroscience, Online

92.

McGeer PL, Schwab C, Staufenbiel M, Hosokawa M, McGeer EG: Amyloid transgenic mice: an incomplete model of Alzheimer disease. Program No. 295.2. 2002 Abstract Viewer/Itinerary Planner. 2002, Washington, DC: Society for Neuroscience, Online

93.

Ebanks RO, Isenman DE: Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol. 1996, 33: 297-309. 10.1016/0161-5890(95)00135-2.PubMed

94.

Ong GL, Mattes MJ: Mouse strains with typical mammalian levels of complement activity. J Immunol Methods. 1989, 125: 147-158. 10.1016/0022-1759(89)90088-4.PubMed

95.

Webster SD, Tenner AJ, Poulos TL, Cribbs DH: The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol Aging. 1999, 20: 297-304. 10.1016/S0197-4580(99)00020-2.PubMed

96.

Cruts M, Van Broeckhoven C: Presenilin mutations in Alzheimer's disease. Hum Mutat. 1998, 11: 183-190. 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M.PubMed

97.

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998, 4: 97-100. 10.1038/nm0198-097.PubMed

98.

Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K: Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001, 158: 1345-1354.PubMedCentralPubMed

99.

Fonseca MI, Zhou J, Botto M, Tenner AJ: Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004, 24: 6457-6465. 10.1523/JNEUROSCI.0901-04.2004.PubMed

100.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996, 274: 99-102. 10.1126/science.274.5284.99.PubMed

101.

Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998, 19: 56-59.PubMed

102.

Coimbra C, Drake M, Boris-Moller F, Wieloch T: Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Stroke. 1996, 27: 1578-1585.PubMed

103.

Sinigaglia-Coimbra R, Cavalheiro EA, Coimbra CG: Postischemic hyperthermia induces Alzheimer-like pathology in the rat brain. Acta Neuropathol (Berl). 2002, 103: 444-452. 10.1007/s00401-001-0487-3.

104.

Lee JH, Kim SR, Bae CS, Kim D, Hong H, Nah S: Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic acid-induced neurotoxicity in rat hippocampus. Neurosci Lett. 2002, 325: 129-133. 10.1016/S0304-3940(02)00256-2.PubMed

105.

Hyman BT, Van Horsen GW, Damasio AR, Barnes CL: Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984, 225: 1168-1170.PubMed

106.

Johnson SA, Lampert-Etchells M, Pasinetti GM, Rozovsky I, Finch CE: Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging. 1992, 13: 641-648. 10.1016/0197-4580(92)90086-D.PubMed

107.

Johnson S, Young-Chan CS, Laping NJ, Finch CE: Perforant path transection induces complement C9 deposition in hippocampus. Exp Neurol. 1996, 138: 198-205. 10.1006/exnr.1996.0058.PubMed

108.

Pasinetti GM, Johnson SA, Rozovsky I, Lampert-Etchells M, Morgan DG, Gordon MN, Morgan TE, Willoughby D, Finch CE: Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol. 1992, 118: 117-125. 10.1016/0014-4886(92)90028-O.PubMed

109.

Rozovsky I, Morgan TE, Willoughby DA, Dugichi-Djordjevich MM, Pasinetti GM, Johnson SA, Finch CE: Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience. 1994, 62: 741-758. 10.1016/0306-4522(94)90473-1.PubMed

110.

Sahu A, Rawal N, Pangburn MK: Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem Pharmacol. 1999, 57: 1439-1446. 10.1016/S0006-2952(99)00044-1.PubMed

111.

Osakabe N, Yasuda A, Natsume M, Yoshikawa T: Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model. Carcinogenesis. 2004, 25: 549-557. 10.1093/carcin/bgh034.PubMed

112.

Youn J, Lee KH, Won J, Huh SJ, Yun HS, Cho WG, Paik DJ: Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. J Rheumatol. 2003, 30: 1203-1207.PubMed

113.

Parejo I, Viladomat F, Bastida J, Schmeda-Hirschmann G, Burillo J, Codina C: Bioguided isolation and identification of the nonvolatile antioxidant compounds from fennel (Foeniculum vulgare Mill.) waste. J Agric Food Chem. 2004, 52: 1890-1897. 10.1021/jf030717g.PubMed

114.

Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res. 2004, 75: 742-750. 10.1002/jnr.20025.PubMed

115.

Spillantini MG, Goedert M: Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998, 21: 428-433. 10.1016/S0166-2236(98)01337-X.PubMed

116.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001, 293: 1487-1491. 10.1126/science.1058189.PubMed

117.

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003, 39: 409-421. 10.1016/S0896-6273(03)00434-3.PubMed

118.

Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A: Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci. 2000, 20: 2589-2601.PubMed

119.

Lauterborn JC, Isackson PJ, Gall CM: Nerve growth factor mRNA-containing cells are distributed within regions of cholinergic neurons in the rat basal forebrain. J Comp Neurol. 1991, 306: 439-446.PubMed

120.

Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A: Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA. 2000, 97: 6826-6831. 10.1073/pnas.97.12.6826.PubMedCentralPubMed

121.

Gearing M, Levey AI, Mirra SS: Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers. J Neuropathol Exp Neurol. 1997, 56: 1363-1370.PubMed

122.

Braun J, Laitko S, Treharne J, Eggens U, Wu P, Distler A, Sieper J: Chlamydia pneumoniae –a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis. 1994, 53: 100-105.PubMedCentralPubMed

123.

Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM: Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999, 46: 6-14. 10.1002/1531-8249(199907)46:1<6::AID-ANA4>3.3.CO;2-D.PubMed

124.

Campbell LA, Kuo CC: Chlamydia pneumoniae –an infectious risk factor for atherosclerosis?. Nat Rev Microbiol. 2004, 2: 23-32. 10.1038/nrmicro796.PubMed

125.

Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP: Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl). 1998, 187: 23-42. 10.1007/s004300050071.

126.

Mahony JB, Woulfe J, Munoz D, Browning D, Chong S, Smieja M: Identification of Chlamydiae pneumoniae in the Alzheimer's brain. World Alzheimer Congress. 2000, 7: 1120-

127.

Ossewaarde JM, Gielis-Proper SK, Meijer A, Roholl PJM: Chlamydia pneumoniae antigens are present in the brains of Alzheimer patients, but not in the brains of patients with other dementias. In Proceedings of the 4th Meeting of European Society for Chlamydia Research: 20–23. Edited by: Saikku P. 2000, 284-August ; Helsinki, Finland

128.

Gieffers J, Reusche E, Solbach W, Maass M: Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. J Clin Microbiol. 2000, 38: 881-882.PubMedCentralPubMed

129.

Nochlin D, Shaw CM, Campbell LA, Kuo CC: Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology. 1999, 53: 1888-PubMed

130.

Ring RH, Lyons JM: Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. J Clin Microbiol. 2000, 38: 2591-2594.PubMedCentralPubMed

131.

Wozniak MA, Cookson A, Wilcock GK, Itzhaki RF: Absence of Chlamydia pneumoniae in brain of vascular dementia patients. Neurobiol Aging. 2003, 24: 761-765. 10.1016/S0197-4580(02)00236-1.PubMed

132.

Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM: Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004, 25: 419-429. 10.1016/S0197-4580(03)00127-1.PubMed

133.

Jawetz E, Melnick JL, Adelberg EA: Review of Medical Microbiology. 1972, Los Altos: Lange Medical Publications, 272-

134.

Hall RT, Strugnell T, Wu X, Devine DV, Stiver HG: Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2. Infect Immun. 1993, 61: 1829-1834.PubMedCentralPubMed

135.

Megran DW, Stiver HG, Bowie WR: Complement activation and stimulation of chemotaxis by Chlamydia trachomatis. Infect Immun. 1985, 49: 670-673.PubMedCentralPubMed

136.

Satou T, Cummings BJ, Head E, Nielson KA, Hahn FF, Milgram NW, Velazquez P, Cribbs DH, Tenner AJ, Cotman CW: The progression of beta-amyloid deposition in the frontal cortex of the aged canine. Brain Res. 1997, 774: 35-43. 10.1016/S0006-8993(97)81684-8.PubMed

137.

Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW: Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging. 2000, 21: 89-96. 10.1016/S0197-4580(00)00093-2.PubMed

138.

Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ, Podlisny MB, Selkoe DJ, Siman R, Greenberg BD, Cotman CW: Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging. 1996, 17: 653-659.PubMed

139.

Cummings BJ, Su JH, Cotman CW, White R, Russell MJ: Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging. 1993, 14: 547-560. 10.1016/0197-4580(93)90038-D.PubMed

140.

Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW: Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem. 1996, 66: 11-23. 10.1006/nlme.1996.0039.PubMed

141.

Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW: The canine as an animal model of human aging and dementia. Neurobiol Aging. 1996, 17: 259-28. 10.1016/0197-4580(95)02060-8.PubMed

142.

Kimura N, Tanemura K, Nakamura S, Takashima A, Ono F, Sakakibara I, Ishii Y, Kyuwa S, Yoshikawa Y: Age-related changes of Alzheimer's disease-associated proteins in cynomolgus monkey brains. Biochem Biophys Res Commun. 2003, 310: 303-311. 10.1016/j.bbrc.2003.09.012.PubMed

143.

Sloane JA, Pietropaolo MF, Rosene DL, Moss MB, Peters A, Kemper T, Abraham CR: Lack of correlation between plaque burden and cognition in the aged monkey. Acta Neuropathol (Berl). 1997, 94: 471-478. 10.1007/s004010050735.

144.

Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS: Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc Natl Acad Sci USA. 1994, 91: 9382-9386.PubMedCentralPubMed

145.

Geula C, Nagykery N, Wu CK: Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol (Berl). 2002, 103: 48-58. 10.1007/s004010100429.

146.

Gearing M, Tigges J, Mori H, Mirra SS: A beta40 is a major form of beta-amyloid in nonhuman primates. Neurobiol Aging. 1996, 17: 903-908. 10.1016/S0197-4580(96)00164-9.PubMed

147.

Schultz C, Hubbard GB, Rub U, Braak E, Braak H: Age-related progression of tau pathology in brains of baboons. Neurobiol Aging. 2000, 21: 905-912. 10.1016/S0197-4580(00)00176-7.PubMed

148.

Schultz C, Hubbard GB, Tredici KD, Braak E, Braak H: Tau pathology in neurons and glial cells of aged baboons. Adv Exp Med Biol. 2001, 487: 59-69.PubMed

149.

Bons N, Jallageas V, Silhol S, Mestre-Frances N, Petter A, Delacourte A: Immunocytochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus. C R Acad Sci III. 1995, 318: 77-83.PubMed

150.

Bons N, Mestre N, Petter A: Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate, Microcebus murinus. Neurobiol Aging. 1992, 13: 99-105. 10.1016/0197-4580(92)90016-Q.PubMed

151.

Giannakopoulos P, Silhol S, Jallageas V, Mallet J, Bons N, Bouras C, Delaere P: Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathol (Berl). 1997, 94: 131-139. 10.1007/s004010050684.

152.

Sparks DL, Schreurs BG: Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA. 2003, 100: 11065-11069. 10.1073/pnas.1832769100.PubMedCentralPubMed

153.

Roertgen KE, Parisi JE, Clark HB, Barnes DL, O'Brien TD, Johnson KH: Abeta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (Gulo gulo). Neurobiol Aging. 1996, 17: 243-247. 10.1016/0197-4580(95)02069-1.PubMed

154.

Tekirian TL, Saido TC, Markesbery WR, Russell MJ, Wekstein DR, Patel E, Geddes JW: N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol. 1998, 57: 76-94.PubMed

155.

Bokisch VA, Muller-Eberhard HJ, Cochrane CG: Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969, 129: 1109-1130. 10.1084/jem.129.5.1109.PubMedCentralPubMed

156.

Gorski JP, Hugli TE, Muller-Eberhard HJ: C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A . 1979, 76: 5299-5302.PubMedCentralPubMed

157.

Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP: Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology . 2000, 49: 171-186. 10.1016/S0162-3109(00)80302-1.PubMed

Title: Using animal models to determine the significance of complement activation in Alzheimer's disease
Author: David A Loeffler
Publication date: 01-12-2004
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2004
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/1742-2094-1-18

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Using animal models to determine the significance of complement activation in Alzheimer's disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2004

Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1β production

Modelling neuroinflammatory phenotypes in vivo

Microglia and neuroinflammation: a pathological perspective

Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury.

Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs

Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis